The Physics Of Eczema: A Math Model Predicts The Minimum Dose To Control Severe Flares

Scientists who study epilepsy and heart arrhythmia have long treated those conditions as physics problems, not just medical ones. Both diseases, in their view, are the body’s control systems breaking down in predictable, mathematically describable ways. Now, researchers are applying that same lens to severe eczema, and the results suggest the approach could one day help estimate how much medication a patient might need to break the cycle of inflammation, and how much moisturizer could keep it from returning.

For the roughly one in 10 adults and one in five children worldwide living with atopic dermatitis, that kind of precision would be a major step forward. In its severe form, the disease resists standard treatments, trapping patients in grinding cycles of itching, open lesions, and sleeplessness. A new theoretical study published in Chaos, argues that by treating severe eczema the same way physicists treat seizure disorders and cardiac arrhythmia, researchers can derive mathematical formulas linking minimum drug doses to each patient’s individual skin biology.

No patients were involved. All results came from computer simulation. But the team, drawn from Pusan National University in South Korea and Arizona State University, argues their framework offers an early quantitative foundation that could support more personalized eczema treatment in the future.

Why Severe Eczema Behaves Like a Physics Problem

In conditions like epilepsy and cardiac arrhythmia, symptoms don’t arise from a single malfunction. They emerge from tipping points in the body’s control systems, and the math behind those tipping points can be studied and, potentially, exploited. Researchers have increasingly applied that same thinking to chronic inflammatory skin conditions, and atopic dermatitis turns out to be a strong fit.

Severe eczema isn’t a fixed state of inflammation. It’s a system caught in a loop, where a compromised skin barrier lets in more pathogens, which fires up the immune response, which further damages the barrier, which lets in more pathogens. In severe cases, that loop locks the disease into a chronic state with no natural exit. Getting out requires outside intervention.

To model that process, the research team tracked three variables: how many pathogens were infiltrating the skin, how intact the skin barrier was, and how many dendritic cells, a type of immune cell that helps lock the body into a sustained inflammatory state, were present. Under the conditions used to simulate severe disease, the model had only one outcome without treatment: a collapsed skin barrier, runaway pathogen levels, and an immune response that couldn’t turn itself off.

The Math Behind Getting Severe Eczema Under Control

Eczema treatment generally follows a two-phase playbook. First comes the “Get Control” phase, where antibiotics or immunosuppressants aggressively knock back inflammation. Then comes the “Keep Control” phase, where emollients and lighter maintenance therapy hold the disease at bay. Doctors have used this approach for years. What they haven’t had is a formula for how much of each treatment a specific patient actually needs.

That’s what this study set out to build. The team ran simulations across thousands of combinations of two patient traits: how easily pathogens pass through the skin barrier, and how effectively the immune system clears them. For the Get Control phase, the minimum antibiotic dose scales in a roughly linear fashion with those traits. Leakier skin requires more antibiotic; a stronger immune response requires less. At a certain level of barrier damage, the model shows a threshold-like shift where antibiotic requirements climb more steeply, suggesting some patients may need earlier and more aggressive treatment than current practice typically delivers.

The Keep Control findings carry even more weight for daily eczema management. Maintaining remission with moisturizer follows what’s known as a power-law relationship with skin permeability, meaning small increases in how leaky the skin is can lead to steep increases in how much emollient is needed. According to the model, emollient demand scales with roughly the sixth power of skin permeability. A patient whose skin barrier is even slightly more compromised than someone else’s may need several times more moisturizer to stay in remission. Stronger immune function reduces that burden, suggesting that the immune system and the skin barrier work together in ways that directly shape how demanding long-term maintenance needs to be.

Both traits the model relies on could, in principle, be approximated using standard clinical measures, including transepidermal water loss, a routine test that gauges how much moisture evaporates through the skin, and immune markers such as IL-4 and IgE levels in the blood, though the paper notes that no formal mapping between those measures and the model’s theoretical parameters has been established yet.

What This Could Mean for Hard-to-Treat Atopic Dermatitis

Severe atopic dermatitis is defined by its resistance to standard care. Extended courses of systemic antibiotics or immunosuppressants carry real costs: side effects, diminishing returns, and growing concerns about antibiotic resistance. Too much medication adds risk without benefit; too little leaves the patient stuck. Right now, there’s no reliable way to know in advance where a given patient lands on that spectrum.

A framework that ties measurable biology to minimum effective doses could eventually allow clinicians to estimate starting doses with a clearer mathematical rationale, rather than adjusting after the fact based on how a patient responds.

The model has limitations. It has not been tested against clinical data, and the traits it measures are theoretical constructs rather than established biomarkers. Biological complexity the model doesn’t yet capture, including cytokine signaling, variation across skin tissue, and random biological noise, could affect how well the predictions hold in real patients. The authors are clear that this is theoretical groundwork, not a treatment protocol.

Similar mathematical approaches have previously helped researchers better understand conditions like epilepsy and cardiac arrhythmia, both of which were once studied in purely theoretical terms before those frameworks began informing clinical thinking. For a condition that affects hundreds of millions of people and remains one of dermatology’s stubbornest problems in its severe form, bringing that kind of rigor to dosing decisions is a promising place to start.

---

Disclaimer: This study is purely theoretical and was conducted through computer simulation only. No human or animal subjects were involved, and the findings have not been validated in a clinical setting. Nothing in this article should be taken as medical advice. Consult a qualified healthcare provider regarding any questions about atopic dermatitis diagnosis or treatment.

---